Celularity (NASDAQ:CELU) Raised to Sell at Wall Street Zen

Key Points

• Wall Street Zen has upgraded Celularity (NASDAQ:CELU) to a "sell" rating, suggesting a bearish outlook for the stock.
• Celularity reported a net loss of ($0.59) earnings per share but exceeded analysts' expectations for revenue with $18.13 million, compared to a forecast of $5.20 million.
• The company's stock has fluctuated between a 12-month low of $1.00 and a high of $5.22, currently trading at around $3.12.

Celularity (NASDAQ:CELU - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "sell" rating in a report issued on Saturday.

Celularity Stock Down 2.6%

Shares of NASDAQ:CELU traded down $0.09 on Friday, reaching $3.21. The company had a trading volume of 18,115 shares, compared to its average volume of 177,032. Celularity has a 52-week low of $1.00 and a 52-week high of $5.22. The firm's 50 day simple moving average is $2.33 and its 200-day simple moving average is $1.98. The firm has a market capitalization of $76.76 million, a PE ratio of -1.21 and a beta of 0.79. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07.

Celularity (NASDAQ:CELU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.91. Celularity had a negative return on equity of 271.88% and a negative net margin of 106.77%. The business had revenue of $18.13 million for the quarter, compared to the consensus estimate of $5.20 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Valmark Advisers Inc. purchased a new position in Celularity during the 2nd quarter worth $98,000. Two Sigma Investments LP purchased a new position in shares of Celularity in the 4th quarter valued at about $93,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Celularity in the 1st quarter valued at about $34,000. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.